Transgenic Mouse Model for Parkinson’s Disease
JHU REF: [C12196]
Invention novelty: This tangible material is a transgenic mice model expressing AIMP2 (Aminoacyl-tRNA synthetase complex-interacting multifunctional protein 2), a protein strongly associated with pathogenesis of Parkinson’s disease (PD).
Value Proposition: No animal models overexpressing human AIMP2 exist. These transgenic mice are tools that can facilitate a better understanding of the role of AIMP2 in PD. In addition, interacting proteins may also be identified. Further, these animals can be used to screen therapeutic agents that prevent AIMP2 induced neuronal loss. Other advantages include:
· Robust expression of AIMP2.
· Tissue/cell specific AIMP2 expression.
· Conditional expression of AIMP2, based on tetracycline induction.
· Can be used to study other disorders.
·
Technical Details
Johns Hopkins researchers have developed transgenic mice expressing a tetracycline-regulated conditional human AIMP2 (hAIMP2) gene with a FLAG-tag at the 3’ end (TetP-AIMP2-FLAG). These transgenic mice express hAIMP2 at high levels under the control of a tetracycline-responsive promoter. Tissue/cell specific expression of hAIMP2 can be achieved by crossing these lines with tetracycline regulated transcription activator (tTA)-expressing driver mice harboring tissue specific promoters. Further, temporal expression of hAIMP2 can be controlled by the administration/withdrawal of doxycycline in the diet.
Looking for Partners: To develop & commercialize the technology as a life science research tool.
Stage of Development: Tangible Material
Data Availability: Under CDA / NDA
Patent Status: None
Publication(s)/Associated Cases: Not at this time.
